Roche and Memory Pharmaceuticals have signed a definitive merger agreement under which Roche will acquire Memory Pharmaceuticals for $50 million in cash. Memory develops drug candidates for the treatment of central nervous system (CNS) disorders such as Alzheimer’s disease and schizophrenia. The company’s nicotinic alpha-7 agonist drug candidates in these disease areas—currently being developed in partnership with Roche—include: R3487/MEM 3454, in Phase II trials for Alzheimer’...